SAN DIEGO, March 31, 2011 /PRNewswire/ -- Accumetrics, Inc., developer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced today that a new recommendation for platelet reactivity testing has been incorporated into the updated 2011 ACCF/AHA Guidelines for the Management of UA/NSTEMI Patients.
The Guidelines, published online in the Journal of the American College of Cardiology(1), signify the growing focus and importance of platelet reactivity testing in a variety of patient populations, including UA/NSTEMI and ACS/PCI. The IIb (B) recommendation suggests that an approach of assessing platelet reactivity in combination with other procedural and patient characteristics may be considered to aid in patient management decisions.
"The addition of platelet reactivity testing to the Guidelines captures what we have already implemented at Scripps," said Matthew J. Price, MD, of the Scripps Translational Science Institute and Scripps Clinic in La Jolla, CA. "We believe that when considering alternative approaches for the management of patients that require antiplatelet therapy, an individualized approach that incorporates platelet reactivity testing is warranted in an attempt to minimize further ischemic events."
The Update also provides guidance on the rapidly expanding treatment options for patients requiring antiplatelet medications. "With the availability of newer antiplatelet agents, it has become challenging for a physician to determine how to manage individual patients," stated Kevin Croce, MD, PhD, Interventional Cardiologist at Brigham and Women's Hospital. "By utilizing platelet reactivity testing as recommended in this new Guideline, we feel we have a clearer picture on how to optimally manage our patients at the Brigham in this increasingly complex clinical setting."
The release of these Guidelines further el
|SOURCE Accumetrics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved